Ro Tops $3.2 Billion in Annualized Revenue After 10-Fold GLP-1 Pivot
Updated
Updated · The New York Times · Nov 11
Ro Tops $3.2 Billion in Annualized Revenue After 10-Fold GLP-1 Pivot
1 articles · Updated · The New York Times · Nov 11
Summary
$3.2 billion in annualized revenue is set to be announced by Ro on Wednesday, marking more than a tenfold increase since the company began overhauling its business in 2022.
The surge followed Ro’s pivot from a telehealth focus on sexual wellness treatments to GLP-1 weight-loss drugs such as Wegovy and Zepbound.
The nine-year-old private company is presenting the results as proof that its reset worked and that demand for GLP-1 treatments extends beyond weight loss.
Ro’s rebound could also revive questions about an eventual IPO, especially after rival Hims & Hers moved into public markets.